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Abstract
Twenty-six unsymmetrical biphenyls were synthesized and evaluated for cytotoxic activity against
DU145, A547, KB and KB-Vin tumor cell lines. Three compounds 27, 35 and 40 showed very potent
activity against the HTCL panel with an IC50 value range of 0.04–3.23 µM. In addition, fourteen
active compounds were all more potent against the drug-resistant KB-Vin cell line than the parental
KB cell line. Preliminary SAR analysis indicated that two bulky substituents on the 2,2′-positions of
unsymmetrical biphenyl skeleton are necessary and crucial for in vitro anticancer activity, thus
providing a good starting point to develop unsymmetrical biphenyls as novel anticancer agents.
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Natural products continue to play a highly significant role today in the discovery and
development of new drugs, new leads and new chemical entities. This fact is particularly
evident in the areas of cancer and infectious diseases, where over 60% and 75% of drugs,
respectively, are of natural origin.1,2 Dibenzocyclooctandiene lignans have been identified as
major bioactive constituents from the traditional Chinese medicinal plant Schizandra
chinese and show a wide variety of interesting biological activities,3, 4 including antiviral,5
anticancer,6, 7 hepatoprotective,8 and anti-inflammatory.9 Recently, it was also reported that
several dibenzocyclooctadiene lignans, such as gomisin A, schisandrins A and B, and
schisantherin A, have activity against cancer multidrug resistance mediated by P-glycoprotein
(P-gp) and effectively restore the action of anticancer drugs,10–12 such as vinblastine,
daunorubicin, doxorubicin, and VP-16.
*Corresponding author. Tel: 86-10-6931690, fax: 86 10 66931690, e-mail address: lanxieshi@yahoo.com.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Bioorg Med Chem Lett. Author manuscript; available in PMC 2009 October 1.
Published in final edited form as:













However, because natural lignans with multiple chiral centers are not always ideal as drug
candidates, even though many total synthesis studies have been reported,13 we were prompted
to use lignans as leads for new compounds with simpler, more accessible structures. The
biphenyl moiety in natural dibenzocyclooctadiene lignans is substituted with methoxy and
methylenedioxy groups at different positions, resulting in either symmetrical (wuweizi C) or
unsymmetrical (wuweizi B) biphenyls, as shown in Figure 1, and this feature is crucial for
biological activity. Structural simplification of the symmetrical wuweizi C to simpler biphenyl
analogs led to the anti-hepatotoxic (liver injury) drugs α-DDB (methyl 4,4′-dimethoxy-5,6,5′,
6′-dimethylenedioxy biphenyl-2,2-dicarboxylate) and bicyclol (Figure 1), which are widely
used medicinally in China and Asia. In our current study, we decided to focus on unsymmetrical
biphenyls, as such compounds have not been previously well explored for cytotoxic activity.
Our goal was to identify novel biphenyl leads with potent anticancer effects, hopefully with
activity against multidrug resistance.
Herein, we report the synthesis of twenty-six unsymmetrical biphenyl compounds (18–43) and
their cytotoxic activity against DU154, A549, KB and drug-resistant KB-Vin cell lines. Among
them, three compounds (27, 35 and 40) showed very promising inhibitory activity against all
tested tumor cells with an IC50 range of 0.04–3.23 µM.
Unsymmetrical biphenyls are frequently prepared by using Stille, Suzuki, Ullmann, and
Grignard cross-coupling reactions. A Suzuki cross-coupling reaction14, 15 of an aryl halide
with an aryl boronic acid offers convenient access to unsymmetrical biaryls with a wide range
of structural diversity. Accordingly, this approach was used to obtain our target compounds
because of phenylboronic acid commercial availability, mild reaction conditions, and a little
or no homocoupling by-products. The different aryl bromide precursors were synthesized as
shown in Scheme 1 following literature methods.16, 17 Using methyl sulfate in strongly basic
conditions, gallic acid was methylated completely to provide methyl 3,4,5-trimethoxybenzoate
(1), followed by bromination to give the aryl bromide 2. In methanol under acidic conditions,
gallic acid was methylated only at the carboxylic acid to yield methyl gallate 6. The three
hydroxyls of 6 were then selectively modified by using different reactions to produce
methylenedioxy 8 or monomethoxy 11. Using 1,3-dibromo-5,5-dimethylhydantoin (DBDMH)
as a brominating reagent,17 bromination of both 8 and 11 occurred regioselectively at the ortho-
position to the free hydroxyl to afford 9 and 12, respectively. Next, the remaining free hydroxyls
in 9 and 12 were converted to methoxy and methylenedioxy groups, respectively, to give
isomeric aryl bromide precursors 10 (methyl 2-bromo-3-methoxy-4,5-
methylenedioxybenzoate) and 13 (methyl 6-bromo-3-methoxy-4,5-methylenedioxybenzoate),
which are desired moieties for building different biphenyl derivatives. The benzaldehyde
analogs of benzoates 2, 10, and 13 were prepared by the following sequence. The carboxylic
esters in 1 and 14 were converted to aldehydes in 4 and 15 by reduction of an intermediate
hydrazone. Bromination of 4 and 15 with Br2 in CH2Cl2 then afforded 2-bromo-3,4,5-
trimethoxybenzaldehyde 5 and a mixture of 2-bromo- and 6-bromo-3-methoxy-4,5-
methylenedioxybenzaldehyde (16 and 17), respectively.
Next, Suzuki cross-coupling reactions were performed using palladium acetate [Pd(AcO)2] as
catalyst in the presence of anhydrous Cs2CO3 to synthesize unsymmetrical biphenyls I–IV as
shown in Scheme 2 and Table 1. Coupling between commercially available phenylboronic acid
(B1) or 2-formylphenyl boronic acid (B2) and the synthetic aryl bromides described above
(2 or 5, 13 or 17, 10 or 16) gave biphenyls of types I (18–20), III (38–40), and IV (41–43),
respectively. Type II biphenyls (28, 29) were prepared by reaction between 2 or 5 with 2-
formyl-4,5-methylenedioxyphenyl boronic acid (B3), which was prepared according to
literature methods.16 After coupling, the aldehyde or methyl ester (substituents R1 and R2) on
the biphenyls was easily converted to various functional groups, including hydroxymethyl,
oxime, carboxylic acid, and various esters, by common synthetic methods, to produce
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additional unsymmetrical biphenyls (21–27, 30–37). The spectroscopic data of all target
biphenyl compounds are shown at endnote 20.
The synthesized biphenyl compounds were tested for in vitro cytotoxic activity against a human
tumor cell line (HTCL) panel, including A549 (lung), DU145 (prostate), KB (nasopharyngeal),
and drug-resistant KB-Vin, according to a reported SRB method.18 Homoharringtonine and
etoposide served as reference antitumor compounds. The structures and bioassay data of all
unsymmetrical biphenyls 18–43 are summarized in Table 1. Among them, 4′,5′-
methylenedioxy-(4,5,6-trimethoxy-biphenyl-2,2′-diyl)bis(methylene)dibenzoate (35) showed
the most potent inhibitory effects with an IC50 value of 0.04 µM against the above four tumor
cell lines.
2,3,4-Trimethoxy-2′,6-bis(2-nitroprop-1-enyl)biphenyl (27) and methyl 2′-formyl-4,5,6-
trimethoxybiphenyl-2-carboxylate (40) were also significantly active with IC50 value ranges
of 0.11–0.51 µM and 0.31–3.23 µM, respectively, against the HTCL panel. Compounds 19,
20, 28, 39, and 43 showed greater activity against DU145 and KB-VIN cell lines than against
the other two cell lines.
From a structure-activity relationship (SAR) viewpoint, various patterns of methoxy and
methylenedioxy substitution on the A and B ring had less impact on inhibitory potency than
changes in the functional groups at the 2,2′-positions of biphenyls. With the 2,2′-substituents
held constant (R1=CHO or COOMe, R2=CHO), Type III (39 and 40; 4-methoxy-5,6-
methylenedioxy substitution) biphenyls were somewhat more potent than Type I (19 and 20;
4,5,6-trimethoxy substitution), II (28 and 29; 4,5,6-trimethoxy-4′,5′-methylenedioxy
substitution), or IV (42 and 43; 4,5-methylendioxy-6-methoxy substitution) compounds.
However, more significant changes in potency were found by changing the substituents at the
2,2′-positions as described below.
Generally, methyl carboxylate (R1) was preferred to an aldehyde on ring A, and an aldehyde
(R2) was better than hydrogen on ring B. This trend was most apparent against DU154 and
KB-Vin cell lines (compare 19/20, 39/40, 42/43). Data for compounds 18–27 and 28–35 (Types
I and II in Table 1) supported our hypothesis that variation of substituents at the biphenyl 2,2′-
positions could greatly affect in vitro anticancer potency. Compounds with hydroxymethyl
(21, 22, 30, 31), dicarbaldehyde oxime (23, 32), methyl acetate (24, 33), and methyl 4-
oxobutanoic acid (25, 34) at these positions showed either no inhibitory activity or were much
less potent than corresponding active compounds 19 and 28 (R1 = R2 = aldehyde), respectively.
In contrast, biphenyls 27 and 35 with two bulky groups, 2-nitroprop-1-enyl and methylbenzoate
respectively, showed significant potency against all tested tumor cell lines.
These results prompted us to consider whether steric compression between adjacent 2,2′-
substituents could alter the biphenyl torsional angle, resulting in a stereo-configuration that
would directly affect the molecular affinity with a target receptor/enzyme and result in different
inhibitory activity against tumor cell lines. Biphenyl configuration (S- or R-) in natural
dibenzocyclooctandiene lignans can play an important role in antiproliferative effects. For
example, wuweizisu B with R-biphenyl configuration is less potent than gomisin N with S-
biphenyl configuration.19 To obtain related information in our study, lactone-linked biphenyls
36 and 37 (Figure 2) were evaluated in the same assays. Although neither compound showed
significant potency, the latter compound with a seven-membered lactone ring was more active
than the former with a six-membered lactone ring. These data suggest that both bigger torsional
angles caused by two bulky substituents on the 2,2′-positions and the configuration of the
biphenyls might play important roles in inhibition of tumor cell growth.
Interestingly, several active compounds (19, 20, 28, 37, 39, 40, 42, and 43) were also 1.4–6.8
times more potent against the drug-resistant KB-Vin cell line than the KB cell line. Thus, we
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hypothesize that the unsymmetrical biphenyl scaffolds are relatively poor substrates for the
drug efflux pump (MDR) and could be developed as novel leads with low potential for drug
resistance development.
In conclusion, twenty-six unsymmetrical biphenyls were synthesized and evaluated in DU145,
A547, KB and KB-Vin tumor cell lines. Three compounds 27, 35 and 40 showed very potent
activity against the HTCL panel with an IC50 value range of 0.04–3.23 µM. In addition,
fourteen active compounds were all more potent against the drug-resistant KB-Vin cell line
than the parental KB cell line. Preliminary SAR analysis indicated that two bulky substituents
on the 2,2′-positions of unsymmetrical biphenyl skeleton are necessary and crucial for in vitro
anticancer activity. Current studies provide a good starting point to develop unsymmetrical
biphenyls as novel anticancer agents. Further lead optimization is ongoing.
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s), 6.77 (1H, s), 6.14 (2H, d, J = 8.0 Hz), 3.87 (3H, s), 3.83 (3H, s), 3.53 (3H, s); ESI-MS m/z: 397
(M+Na+). 33: Yield 92%, white solid, mp 154–155 °C; 1H-NMR 6.95 (1H, s), 6.78 (1H, s), 6.64
(1H, s), 6.02 (2H, s), 4.73–4.76 (4H, m), 3.92 (3H, s), 3.89 (3H, s), 3.64 (3H, s), 2.04 (3H, s), 2.00
(3H, s); ESI-MS m/z: 455 (M+Na+). 34: Yield 91%, 1H NMR 7.00 (1H, s), 6.89 (1H, s), 6.71 (1H,
s), 6.07 (2H, s), 4.63 (4H, m), 3.84 (3H, s), 3.76 (3H, s), 3.51 (3H, s), 2.40 (8H, m); ESI-MS m/z:
571 (M+Na+). 35: Yield 94%; white gum; 1H NMR 7.96 (4H, m), 7.50 (2H, m), 7.38 (4H, m), 7.05
(1H, s), 6.86 (1H, s), 6.73 (1H, s), 6.00 (2H, d, J = 8.8 Hz), 5.06-5.03 (4H, m), 3.89 (6H, s), 3.66
(3H, s); ESI-MS m/z: 579 (M+Na+). 36: Yield 11%; pale yellow solid, mp 191–194 °C; 1H NMR
8.33 (1H, s), 7.72 (1H, s), 6.87 (1H, s), 6.07 (2H, s), 4.04 (3H, s), 4.00 (3H, s), 3.96 (3H, s); ESI-MS
m/z: 353 (M+Na+). 37: Yield 98%; white solid, mp 163–164 °C; 1H NMR 7.26 (1H, s), 6.92 (1H,
s), 6.03 (2H, d, J = 16 Hz), 4.93 (1H, d, J = 12 Hz), 4.81 (1H, d, J = 12 Hz), 3.99 (3H, s), 3.95 (3H,
s), 3.66 (3H, s); ESI-MS m/z 367 (M+Na+). 38: Yield 80%; white solid, mp 106–107 °C; 1H NMR
9.78 (1H, s), 7.48 (3H, m), 7.42 (2H, m), 7.36 (1H, s), 6.11 (2H, s), 4.00 (3H, s); ESI-MS m/z: 279
(M+Na+). 39: Yield 70%; white solid, mp 112–114 °C; 1H NMR 9.95 (1H, s), 9.68 (1H, s), 8.07
(1H, dd, J = 1.6 & 7.6 Hz), 7.70 (1H, ddd, J = 1.6 & 7.6 Hz), 7.61(1H, dd, J = 7.6 Hz), 7.39 (1H, s),
7.37 (1H, dd, J = 1.6 & 7.6 Hz), 6.13 (2H, s), 3.83 (3H, s); ESI-MS m/z: 307 (M+Na+). 40: Yield
84%; white solid, mp 121–122 °C; 1H NMR 9.89 (1H, s), 8.02 (1H, dd, J = 1.2 & 7.6 Hz), 7.63 (1H,
dd, J = 1.2 & 7.6 Hz), 7.52 (1H, d, J = 7.6 Hz), 7.40 (1H, s), 7.27 (1H, d, J = 7.6 Hz), 6.01 (2H,s),
4.00 (3H, s), 3.58 (3H, s); ESI-MS m/z: 337 (M+Na+). 41: Yield 80%; white solid, mp 89–91 °
C; 1H NMR 9.52 (1H, s), 7.43 (3H, m), 7.30 (2H, m), 7.24 (1H, s), 6.10 (2H, s), 3.82 (3H, s). ESI-
MS m/z: 279 (M+Na+). 42: Yield 70%; white solid, mp 125–126 °C; 1H NMR 9.86 (1H, s), 9.47
(1H, s), 8.06 (1H, dd, J = 1.6 & 7.6 Hz), 7.67 (1H, dd, J = 1.6 & 7.6 Hz), 7.64 (1H, d, J = 7.6 Hz),
7.27 (1H, s), 7.25 (1H, d, J = 7.6 Hz), 6.13 (2H, s), 3.83 (3H, s); ESI-MS m/z: 295 (M+Na+). 43:
Yield 70%; white solid, mp 88–90 °C; 1H NMR 9.84 (1H, s), 8.02 (1H, dd, J = 1.2 & 7.6 Hz), 7.58
(1H, dd, J = 1.2 & 7.6 Hz), 7.50 (1H, d, J = 7.6 Hz), 7.24 (1H, s), 7.15 (1H, d, J = 7.6 Hz), 6.10 (2H,
s), 3.78 (3H, s), 3.52 (3H, s); ESI-MS m/z: 337 (M+Na+). All 1H-NMR were measured in solvent
CDCl3 unless indicated.
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Structures of natural dibenzocyclooctadiene lignans and biphenyl derivatives
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Structures of lactone-linked biphenyl derivatives
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Synthesis of aryl bromide precursors. i. Me2SO4/NaOH aq, rt, 1.5 h; ii. Br2/CH2Cl2, 0 °C, 1–
3 h; iii. NH2NH2·H2O, 95 °C, 3 h; iv. K3Fe(CN)6/NH3·H2O, toluene/H2O, r.t., 0.5–1.5 h; v.
MeOH/H2SO4, reflux, 5 days; vi. (EtO)3CH/H+, benzene, reflux, 16 h; vii. a. BnBr, K2CO3,
DMF, 70 °C, 1.5 h, 90%; b. HCl aq. (2%), MeOH, r.t., 2 h, 99%; c. CH2Cl2/K2CO3, DMF,
105 °C, 6 h, 96%; d. TiCl4/CHCl3, rt, 12 h, 90%; viii. DBDMH/CHCl3, r.t., 10 h; ix.
Me2SO4/NaOH aq, Na2B4O7, rt, 5 h; x. CH2Cl2/K2CO3, DMF, 105 °C, 6 h.
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Synthesis of unsymmetrical biphenyls. i. Pd(OAc)2, PPh3, Cs2CO3, DME, 70 °C, 2–10 h; ii.
NaBH4/MeOH, rt, 1–2 h, 99%; iii. NH2OH·HCl, NaOH aq./C2H5OH, rt, 2 h, 81–98%; iv.
CH3CH2NO2, n-BuNH2/HOAc, toluene, reflux, 3 days, 63%; v. R3COCl, Py, rt, 12 h, 90–
96%; vi. NaOH/ H2O, 100 °C, 4 h, 70%.
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